BTIG has upgraded Solventum Corp (SOLV) to a Buy rating from Neutral, effective December 1, 2025. This shift indicates a more optimistic outlook on the company’s prospects, potentially driven by improved fundamentals or better-than-expected business performance.
Headquartered in St. Paul, Minnesota, Solventum Corp operates in the health care sector, employing 22,000 full-time staff. The company, which went public on March 26, 2024, has segments that include MedSurg, Dental Solutions, and Health Information Systems. MedSurg offers a range of medical solutions, while Dental Solutions provides dental and orthodontic products. Health Information Systems focuses on software solutions for healthcare systems.
As of the latest financial snapshot on November 27, 2025, Solventum Corp has a market capitalization of $14.8 billion and a trailing twelve-month price-to-earnings ratio of 9.71, with earnings per share at 8.69. The company reported a surprise in its Q3 2025 earnings, delivering an EPS of $1.50 against an estimate of $1.46, marking a 2.7% positive variance.
Upcoming earnings are slated for August 5, 2026, with estimates of $1.67 EPS and $2.1 billion in revenue. The analyst consensus currently stands at Buy, with 4 Strong Buy, 6 Buy, 10 Hold, and 1 Sell ratings among a total of 21 analysts.
Analyst ratings and price targets provide insights based on research and financial models. However, such assessments are contingent on various assumptions that may not always materialize as anticipated. Investors should consider multiple factors, including company fundamentals and industry trends, before making investment decisions. Analyst opinions should be one of many inputs in this process.
The recent upgrade by BTIG underscores a growing confidence in Solventum Corp's strategic direction and market positioning.